Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
2863 | 2053 | 33.8 | 78% |
Classes in level above (level 2) |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | CYP2C9 | Author keyword | 412 | 63% | 20% | 420 |
2 | VKORC1 | Author keyword | 382 | 81% | 11% | 233 |
3 | WARFARIN | Author keyword | 142 | 19% | 33% | 675 |
4 | CYP4F2 | Author keyword | 66 | 74% | 2% | 50 |
5 | ACENOCOUMAROL | Author keyword | 56 | 48% | 4% | 87 |
6 | CYP2C9 POLYMORPHISM | Author keyword | 26 | 87% | 1% | 13 |
7 | CYTOCHROME P4502C9 | Author keyword | 23 | 69% | 1% | 20 |
8 | DOSING ALGORITHM | Author keyword | 18 | 65% | 1% | 17 |
9 | R WARFARIN | Author keyword | 18 | 83% | 0% | 10 |
10 | CYP2C93 | Author keyword | 18 | 89% | 0% | 8 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | CYP2C9 | 412 | 63% | 20% | 420 | Search CYP2C9 | Search CYP2C9 |
2 | VKORC1 | 382 | 81% | 11% | 233 | Search VKORC1 | Search VKORC1 |
3 | WARFARIN | 142 | 19% | 33% | 675 | Search WARFARIN | Search WARFARIN |
4 | CYP4F2 | 66 | 74% | 2% | 50 | Search CYP4F2 | Search CYP4F2 |
5 | ACENOCOUMAROL | 56 | 48% | 4% | 87 | Search ACENOCOUMAROL | Search ACENOCOUMAROL |
6 | CYP2C9 POLYMORPHISM | 26 | 87% | 1% | 13 | Search CYP2C9+POLYMORPHISM | Search CYP2C9+POLYMORPHISM |
7 | CYTOCHROME P4502C9 | 23 | 69% | 1% | 20 | Search CYTOCHROME+P4502C9 | Search CYTOCHROME+P4502C9 |
8 | DOSING ALGORITHM | 18 | 65% | 1% | 17 | Search DOSING+ALGORITHM | Search DOSING+ALGORITHM |
9 | R WARFARIN | 18 | 83% | 0% | 10 | Search R+WARFARIN | Search R+WARFARIN |
10 | CYP2C93 | 18 | 89% | 0% | 8 | Search CYP2C93 | Search CYP2C93 |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | CYP2C9 | 309 | 58% | 17% | 353 |
2 | CYTOCHROME P4502C9 | 276 | 70% | 11% | 229 |
3 | VKORC1 | 203 | 71% | 8% | 163 |
4 | K EPOXIDE REDUCTASE | 142 | 61% | 7% | 150 |
5 | DOSE REQUIREMENTS | 102 | 48% | 8% | 154 |
6 | CYP2C9 GENOTYPE | 96 | 91% | 2% | 40 |
7 | VKORC1 HAPLOTYPES | 94 | 89% | 2% | 42 |
8 | VKORC1 GENOTYPES | 91 | 89% | 2% | 41 |
9 | WARFARIN DOSE REQUIREMENTS | 88 | 78% | 3% | 59 |
10 | DOSING ALGORITHMS | 86 | 96% | 1% | 26 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Oral anticoagulation: a critique of recent advances and controversies | 2015 | 2 | 81 | 64% |
Influence of CYP2C9 and VKORC1 on Patient Response to Warfarin: A Systematic Review and Meta-Analysis | 2012 | 30 | 126 | 88% |
Cytochrome P4502C9 polymorphisms: a comprehensive review of the in-vitro and human data | 2002 | 357 | 70 | 87% |
Prediction of warfarin dose: why, when and how? | 2012 | 29 | 59 | 69% |
Fever as a Risk Factor for Increased Response to Vitamin K Antagonists: A Review of the Evidence and Potential Mechanisms | 2015 | 1 | 17 | 59% |
Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin-treated patients: A systematic review and meta-analysis | 2013 | 20 | 70 | 77% |
Pharmacogenetics of Warfarin | 2010 | 42 | 41 | 93% |
Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement- A systematic review and meta analysis | 2010 | 37 | 36 | 100% |
Impact of the CYP4F2 p.V433M Polymorphism on Coumarin Dose Requirement: Systematic Review and Meta-Analysis | 2012 | 18 | 48 | 88% |
Association of warfarin dose with genes involved in its action and metabolism | 2007 | 184 | 60 | 50% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | UNITE GERIATRIE AIGUE | 2 | 44% | 0.2% | 4 |
2 | DRUG SAFETY UNIT | 2 | 14% | 0.7% | 15 |
3 | PERSONALIZED GENET MED | 2 | 67% | 0.1% | 2 |
4 | ANTICOAGULAT CLIN | 2 | 22% | 0.4% | 8 |
5 | GENOME QUEBEC MONTREAL HEART | 2 | 43% | 0.1% | 3 |
6 | ST ANTOINE UNIV HOSP | 2 | 28% | 0.2% | 5 |
7 | ANTICOAGULAT | 1 | 100% | 0.1% | 2 |
8 | CLIN PHARM CLIN CHEM HAEMATOL | 1 | 100% | 0.1% | 2 |
9 | METHODIST INPATIENT PHYS | 1 | 100% | 0.1% | 2 |
10 | MULTIDISCIPLINARY MOL BIOL DIAGNOST | 1 | 100% | 0.1% | 2 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000167030 | INTERNATIONAL SENSITIVITY INDEX//PROTHROMBIN TIME//INTERNATIONAL NORMALIZED RATIO |
2 | 0.0000127339 | ANTICOAGULANT RESISTANCE//VERTEBRATE PESTS UNIT//VKOR |
3 | 0.0000116441 | PROTHROMBIN COMPLEX CONCENTRATE//PROTHROMBIN COMPLEX CONCENTRATES//ANTICOAGULATION REVERSAL |
4 | 0.0000101776 | PHARMACOGENOMICS//PERSONALIZED MEDICINE//PROGRAM PERSONALIZED MED TARGETED THER EUT |
5 | 0.0000081511 | CYP2D6//DEBRISOQUINE//CYP2C19 |
6 | 0.0000069367 | ATRIAL FIBRILLATION//WARFARIN//CITY HOSP |
7 | 0.0000062912 | CYP3A//COCKTAIL//MECHANISM BASED INHIBITION |
8 | 0.0000057254 | POTENTIAL DRUG DRUG INTERACTION//POTENTIAL DRUG DRUG INTERACTIONS//PRESCRIPTIONS SCREENING |
9 | 0.0000053691 | ANTICOAGULANT RODENTICIDES//SUPERWARFARIN//BRODIFACOUM |
10 | 0.0000050160 | SITE OF METABOLISM//ACTIVE SITE TOPOLOGY//COMPUTAT CHEM MOL STRUCT |